Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

Oct 19 2016

• By Brenda Sandburg

Listen to this article

Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.

3D illustration of molecular structure and communication concept on dark background. science, connection, biology, medicine

Coherus BioSciences Inc. is betting big on biosimilars, and is one of an elite group of pure play biosimilar specialists looking to compete against significantly bigger players. Though Coherus is a relatively little-known newcomer, it is one of just seven drug companies to have submitted a biosimilar application to FDA, along with marquee names like Sandoz Inc., Amgen Inc. and Pfizer Inc. – and it has the chance to be first to market in some lucrative categories.

The Redwood City, Calif.-based upstart could be the first to launch a biosimilar version of Amgen's blockbuster Neulasta (pegfilgrastim). Coherus...

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio
Jan 23 2026
• By Jessica Merrill
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Quick Listen: Scrip’s Five Must-Know Things
Dec 09 2025
• By Reed Miller
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Article Without An Author Listed
Nov 19 2025
Here is a short description.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj